Amphastar Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Amphastar Pharmaceuticals hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.2%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	US$3.16
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

May 30

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Mar 04

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Jan 04

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Dec 20

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Dec 03

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Sep 03

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Aug 17

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Jun 02

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

May 11

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Mar 02

Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Feb 07

Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Jan 24

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Nov 02

Amphastar: A Pharmaceutical Growth Stock

Oct 06

Amphastar wins FDA approval for Epinephrine pre-filled syringes

Aug 16

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

Aug 08

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 24

Amphastar generic vasopressin for increasing blood pressure gets FDA approval

Jul 19

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Jun 10

Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio

May 13

I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease

Apr 23

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Feb 13

Amphastar Pharma: A Well-Run, Diversified Mid Cap

Jan 26

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von AMPH in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von AMPH gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Amphastar Pharmaceuticals Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von AMPH im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (AMPH)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Pharmaceuticals)	2.2%
Analystenprognose in 3 Jahren (AMPH)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von AMPH im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von AMPH im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von AMPH, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da AMPH keine Ausschüttungen gemeldet hat.

Amphastar Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Co-founder exercised options to buy US$4.1m worth of stock.

Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

Amphastar Pharmaceuticals: Buy When Fear Is Overblown

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

Reassessing Amphastar Pharmaceuticals

First quarter 2024 earnings released: EPS: US$0.90 (vs US$0.54 in 1Q 2023)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Price target decreased by 7.3% to US$62.60

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Co-founder exercised options and sold US$13m worth of stock

CFO, Executive VP of Finance notifies of intention to sell stock

Insider recently sold US$590k worth of stock

Investor sentiment deteriorates as stock falls 15%

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Full year 2023 earnings: EPS misses analyst expectations

Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023

Amphastar Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chairman of the Board notifies of intention to sell stock

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Insider exercised options and sold US$343k worth of stock

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Lead Independent Director recently sold US$263k worth of stock

Lead Independent Director notifies of intention to sell stock

Consensus EPS estimates increase by 14%

Investor sentiment improves as stock rises 22%

Third quarter 2023 earnings released: EPS: US$1.01 (vs US$0.33 in 3Q 2022)

Amphastar Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

CFO, Executive VP of Finance notifies of intention to sell stock

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Executive VP of Sales notifies of intention to sell stock

Insider recently sold US$730k worth of stock

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Amphastar Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Consensus EPS estimates increase by 21%

CFO, Executive VP of Finance notifies of intention to sell stock

Investor sentiment improves as stock rises 20%

Price target increased by 17% to US$50.50

Independent Director notifies of intention to sell stock

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Insider recently sold US$316k worth of stock

Investor sentiment improves as stock rises 18%

Lead Independent Director notifies of intention to sell stock

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

First quarter 2023 earnings released: EPS: US$0.54 (vs US$0.50 in 1Q 2022)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 09, 2023

Investor sentiment deteriorates as stock falls 15%

CFO, Executive VP of Finance notifies of intention to sell stock

CFO, Executive VP of Finance notifies of intention to sell stock

Consensus EPS estimates increase by 15%

CFO, Executive VP of Finance notifies of intention to sell stock

Price target increased by 7.4% to US$40.00

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Full year 2022 earnings released: EPS: US$1.88 (vs US$1.30 in FY 2021)

Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$37.25

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Amphastar Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Price target decreased to US$38.75

Amphastar: A Pharmaceutical Growth Stock

Amphastar wins FDA approval for Epinephrine pre-filled syringes

Key Executive exercised options and sold US$250k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Amphastar Pharmaceuticals, Inc. Announces Executive Changes

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

Independent Director notifies of intention to sell stock

Amphastar Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Price target increased to US$42.00